Feng Bi, Yanqiao Zhang, Yabing Guo, Zhongyuan Xu, Shanzhi Gu, Yao Huang, Mingxu Da, Zhiyu Chen, Chaoying Liu, Yaozhen Pan, Hao Ying, Ming Huang, Zheng Wang, Jianbing Wu, Jun Zhao, Ranran Sun, Shujun Yang, Xiaokui Yu, Hui Li, Shilin Xue. "First-line iparomlimab and tuvonralimab (QL1706) or iparomlimab (QL1604) + bevacizumab (BEV) for unresectable hepatocellular carcinoma (HCC): Updated results from the phase Ib/II DUBHE-H-106 study.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.4_suppl.579